Stockscreener 앱 받기
6.34
2.76%
-0.18
시간 외 거래:
6.35
0.010
+0.16%
전일 마감가:
$6.52
열려 있는:
$6.57
하루 거래량:
687.90K
Relative Volume:
0.77
시가총액:
$198.79M
수익:
$19.09M
순이익/손실:
$-82.13M
주가수익비율:
-2.2622
EPS:
-2.8026
순현금흐름:
$-70.00M
1주 성능:
-3.65%
1개월 성능:
-13.62%
6개월 성능:
-61.27%
1년 성능:
-78.11%
1일 변동 폭
$6.29
$6.82
1주일 범위
$6.285
$7.0929
52주 변동 폭
$6.285
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
명칭
Lenz Therapeutics Inc
전화
858-925-7000
주소
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
6.34 | 207.88M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2025-03-18 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-04-10 | 개시 | Citigroup | Buy |
| 2024-03-27 | 개시 | Piper Sandler | Overweight |
| 2023-02-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-25 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-14 | 개시 | BTIG Research | Buy |
| 2022-03-22 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 개시 | Morgan Stanley | Overweight |
| 2021-07-20 | 개시 | SVB Leerink | Outperform |
모두보기
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
RA Capital-linked entities receive 22,100 LENZ (LENZ) options via director grant - Stock Titan
LENZ (NASDAQ: LENZ) director awarded 22,100 stock options at $6.63 strike - Stock Titan
LENZ Therapeutics grants 22,100 options to director | LENZ Insider Trading - Stock Titan
Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting - Investing.com Australia
[8-K] LENZ Therapeutics, Inc. Reports Material Event - Stock Titan
CCCC News | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
LENZ Technical Analysis & Stock Price Forecast - Intellectia AI
Everest medicines acquires greater china rights to aceclidine presbyopia eye drop (VIZZ) - Ophthalmology Times
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ) - Ophthalmology Times
LENZ Therapeutics adds China partner for presbyopia drug VIZZ - Yahoo Finance
Everest Medicines acquires Greater China rights for LENZ Therapeutics' presbyopia eyedrop VIZZ® - MSN
LENZ Therapeutics to Receive VIZZ Payments From Everest-Corxel Deal - marketscreener.com
LENZ Therapeutics (LENZ) Stock Price, News & Analysis - MarketBeat
LENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater China - Quiver Quantitative
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ - LENZ Therapeutics
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China - The Norfolk Daily News
LENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10 - MSN
Eye drop company LENZ heads to three investor conferences in June - Stock Titan
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Earnings call transcript: LENZ Therapeutics sees growth in Q1 2026 By Investing.com - Investing.com Nigeria
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
Users - FinancialContent
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts - Yahoo Finance
LENZ Therapeutics Q1 2026 earnings preview - MSN
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade - Yahoo Finance
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts - Sahm
LENZ Stock Price, Quote & Chart | LENZ THERAPEUTICS INC (NASDAQ:LENZ) - ChartMill
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - 富途牛牛
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
LENZ Therapeutics, Inc. (LENZ) reports Q1 loss, beats revenue estimates - MSN
Citi Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
LENZ Therapeutics Company Profile & Introduction - Moomoo
MSN Money - MSN
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $12 to $60 - Moomoo
Lenz Therapeutics price target raised to $31 from $29 at BofA - TipRanks
LENZ Therapeutics stock price target lowered to $38 by H.C. Wainwright - Investing.com Nigeria
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright - TipRanks
LENZ Therapeutics Q1 earnings call highlights - MSN
Lenz outlines sales force reaching 15,000 eye care professionals by quarter end as VIZZ adoption actions roll out - MSN
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler - TipRanks
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales - Investing.com
Piper Sandler cuts Lenz Therapeutics stock rating on slow sales By Investing.com - Investing.com Australia
Lenz Therapeutics Inc (LENZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lenz Therapeutics Inc 주식 (LENZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 27 '26 |
Buy |
8.95 |
28,089 |
251,411 |
77,289 |
| Chevallard Daniel R. | Chief Financial Officer |
Mar 27 '26 |
Buy |
8.57 |
7,500 |
64,275 |
12,886 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Option Exercise |
2.08 |
10,000 |
20,800 |
14,733 |
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
2.60%
0.94%
자본화:
|
볼륨(24시간):